Cargando…
Precision oncology using ex vivo technology: a step towards individualised cancer care?
Despite advances in cancer genomics and the increased use of genomic medicine, metastatic cancer is still mostly an incurable and fatal disease. With diminishing returns from traditional drug discovery strategies, and high clinical failure rates, more emphasis is being placed on alternative drug dis...
Autores principales: | Williams, Sophie T., Wells, Greg, Conroy, Samantha, Gagg, Hannah, Allen, Richard, Rominiyi, Ola, Helleday, Thomas, Hullock, Katie, Pennington, Catherine E. W., Rantala, Juha, Collis, Spencer J., Danson, Sarah J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884776/ https://www.ncbi.nlm.nih.gov/pubmed/36184897 http://dx.doi.org/10.1017/erm.2022.32 |
Ejemplares similares
-
Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients
por: Gagg, Hannah, et al.
Publicado: (2023) -
DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies
por: Rominiyi, Ola, et al.
Publicado: (2021) -
The ‘Ins and Outs’ of Early Preclinical Models for Brain Tumor Research: Are They Valuable and Have We Been Doing It Wrong?
por: Rominiyi, Ola, et al.
Publicado: (2019) -
DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells
por: Vanderlinden, Aurelie, et al.
Publicado: (2023) -
Tumour treating fields therapy for glioblastoma: current advances and future directions
por: Rominiyi, Ola, et al.
Publicado: (2020)